These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 29160059

  • 1. Deuterated Drug Molecules: Focus on FDA-Approved DeutetrabenazinePublished as part of the Biochemistry series "Biochemistry to Bedside".
    DeWitt SH, Maryanoff BE.
    Biochemistry; 2018 Feb 06; 57(5):472-473. PubMed ID: 29160059
    [No Abstract] [Full Text] [Related]

  • 2. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM.
    Drugs Today (Barc); 2017 Feb 06; 53(2):89-102. PubMed ID: 28387387
    [Abstract] [Full Text] [Related]

  • 3. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA, Proctor GJ, Stahl SM.
    Clin Schizophr Relat Psychoses; 2018 Jan 06; 11(4):214-220. PubMed ID: 29341821
    [Abstract] [Full Text] [Related]

  • 4. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM.
    CNS Spectr; 2018 Aug 06; 23(4):239-247. PubMed ID: 30160230
    [Abstract] [Full Text] [Related]

  • 5. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr 23; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract] [Full Text] [Related]

  • 6. Tetrabenazine.
    Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P.
    Nat Rev Drug Discov; 2009 Jan 23; 8(1):17-8. PubMed ID: 19116624
    [No Abstract] [Full Text] [Related]

  • 7. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals.
    Russak EM, Bednarczyk EM.
    Ann Pharmacother; 2019 Feb 23; 53(2):211-216. PubMed ID: 30136594
    [Abstract] [Full Text] [Related]

  • 8. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Jankovic J.
    Expert Rev Neurother; 2006 Jan 23; 6(1):7-17. PubMed ID: 16466307
    [Abstract] [Full Text] [Related]

  • 9. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2017 Nov 23; 71(11):. PubMed ID: 29024264
    [Abstract] [Full Text] [Related]

  • 10. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP.
    J Clin Psychiatry; 2020 Sep 29; 81(6):. PubMed ID: 32991793
    [Abstract] [Full Text] [Related]

  • 11. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.
    N Engl J Med; 2017 Jun 29; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract] [Full Text] [Related]

  • 12. Valbenazine: First Global Approval.
    Kim ES.
    Drugs; 2017 Jul 29; 77(10):1123-1129. PubMed ID: 28578484
    [Abstract] [Full Text] [Related]

  • 13. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease.
    Moondra P, Jimenez-Shahed J.
    Expert Rev Neurother; 2024 Sep 29; 24(9):849-863. PubMed ID: 38982802
    [Abstract] [Full Text] [Related]

  • 14. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T, Yilmaz R, Akbostanci MC.
    Parkinsonism Relat Disord; 2020 May 29; 74():36-37. PubMed ID: 32311641
    [No Abstract] [Full Text] [Related]

  • 15. Valbenazine-induced parkinsonism.
    Akbar U, Kim DS, Friedman JH.
    Parkinsonism Relat Disord; 2020 Jan 29; 70():13-14. PubMed ID: 31785443
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N, Jankovic J.
    Drugs; 2018 Apr 29; 78(5):525-541. PubMed ID: 29484607
    [Abstract] [Full Text] [Related]

  • 17. First deuterated drug approved.
    Schmidt C.
    Nat Biotechnol; 2017 Jun 07; 35(6):493-494. PubMed ID: 28591114
    [No Abstract] [Full Text] [Related]

  • 18. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N, Jimenez-Shahed J.
    Neurodegener Dis Manag; 2019 Apr 07; 9(2):59-71. PubMed ID: 30702019
    [Abstract] [Full Text] [Related]

  • 19. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO, Philbin M, Carroll B.
    Expert Opin Pharmacother; 2019 Dec 07; 20(18):2209-2221. PubMed ID: 31613641
    [Abstract] [Full Text] [Related]

  • 20. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J, Shi WX, Dashtipour K.
    Pharmacol Ther; 2020 Aug 07; 212():107580. PubMed ID: 32454050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.